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Summary
Congenital melanocytic naevi (CMN) are a known risk factor for melanoma, with the
greatest risk currently thought to be in childhood. There has been controversy over
the years about the incidence of melanoma, and therefore over the clinical manage-
ment of CMN, due partly to the difficulties of histological diagnosis and partly to
publishing bias towards cases of malignancy. Large cohort studies have demonstrated
that melanoma risk in childhood is related to the severity of the congenital pheno-
type. New understanding of the genetics of CMN offers the possibility of improve-
ment in diagnosis of melanoma, identification of those at highest risk, and new
treatment options. We review the world literature and our centre’s experience over
the last 25 years, including the molecular characteristics of melanoma in these
patients and new melanoma incidence and outcome data from our prospective
cohort. Management strategies are proposed for presentation of suspected melanoma
of the skin and the central nervous system in patients with CMN, including use of oral
mitogen-activated protein kinase kinase inhibitors in NRAS-mutated tumours.
What’s already known about this topic?
• Multiple congenital melanocytic naevi (CMN) are the greatest risk factor for paedi-
atric melanoma.
• Different clinical phenotypes have different risks of malignancy; however, the over-
all absolute risk for all types of CMN taken together is low.
• CMN can develop proliferative nodules that can cause diagnostic uncertainty and
lead to repeated resections.
• Histology in patients with CMN is difficult and often requires specialist review.
• Melanoma in CMN is highly aggressive.
What does this study add?
• In our prospective cohort, the strongest statistical risk factor for all-site melanoma
in childhood is an abnormal screening MRI of the central nervous system (CNS) in
the first months of life, and in this group the incidence is 12%.
• Where melanoma does arise in children with multiple CMN, a primary in the CNS
is at least as common as in the skin.
• CNSmelanoma currently has 100%mortality, but oral mitogen-activated protein kinase
kinase inhibition in NRAS-mutation mosaic patients may improve symptom control.
• Management strategies are proposed for the presentation of a possible malignancy
in the skin or CNS.
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Congenital melanocytic naevus and congenital
melanocytic naevus syndrome
A congenital melanocytic naevus (CMN) is an abnormal but
benign collection of naevus cells within the skin at birth.
Small single CMN are found in 1% of neonates,1,2 where
small is defined as < 15-cm projected adult size.3 However,
there is a spectrum of size and number of CMN, and in
around 1 in 20 000 births an infant is born with a naevus of
> 20-cm-diameter projected adult size,4 which is then usually
associated with other smaller CMN. In the most severe cuta-
neous phenotypes, up to 80% of the skin surface area is cov-
ered in naevi. The naevi are permanent, and grow in
proportion to the child, covering the same anatomical area of
skin as is affected at birth.
As with many birthmarks, CMN is the result of a mutation
in utero, after the embryo has already begun to develop, and
which therefore leads to mosaicism. When the mutation
occurs early enough in development it can hit a multipotent
progenitor cell, which can lead to multiple CMN on the skin
and sometimes to involvement of other organ systems. Thus
in patients with multiple CMN, the same mutation has been
found in different CMN on the skin, and in melanocytic and
nonmelanocytic lesions of the central nervous system (CNS),
but not in unaffected skin or blood.5 Furthermore, such
patients can have subtle endocrine dysfunction,6 characteristic
facial features7 and, very rarely, metabolic bone disease, which
has so far always been associated with a co-occurring epider-
mal naevus.8 Where any extracutaneous systems are involved,
the term ‘CMN syndrome’ has been proposed7 as a more
appropriate term than ‘neurocutaneous melanosis’, as melano-
sis is only a subset of the congenital neurological abnormali-
ties that can occur in patients with CMN. This terminology
brings the condition into line with existing classification of
other types of congenital naevi.
Benign proliferations
Benign proliferations within CMN are common, primarily but
not exclusively arising in large or multiple naevi, and knowl-
edge of their characteristics is helpful in monitoring for malig-
nancy. Clinical appearances are highly variable (Fig. 1), but
(a)
(c) (d) (e)
(b)
Fig 1. Benign proliferative nodules, which develop commonly within large congenital melanocytic naevi. (a, b, e) Nodules more typical of the
‘classic proliferative nodule’ type; (d) typical ‘neuroid’ type growths; (c) multiple benign proliferations that are not typical of either category.
Written consent was obtained for publication.
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the most common can be divided into two categories pro-
posed here: ‘classic’ proliferative nodules and neuroid over-
growth. Classic proliferative nodules have a well-defined edge,
a round or oval outline and a smooth and sometimes shiny
surface, and are soft or firm but not hard. They are usually
05–2 cm in diameter but can be up to 5 cm, and can be any
colour, but are often pink or less darkly pigmented than the
surrounding CMN (Fig. 1a, b, e). They are most frequently
congenital, but can appear at any time in childhood, when
they generally grow over a period of weeks and then stabilize.
Histopathology shows a nodular lesion composed of a mix-
ture of morphological cell types with a pushing border, which
often distorts the surrounding structures. In contrast to mela-
noma, there is generally no necrosis, cytological atypia or
increased proliferative activity (Fig. 2). If cytological atypia is
present, cells are usually homogeneous and mitotic activity is
relatively low, although very exceptionally these nodules can
be quite proliferative.9 Classical proliferative nodules are often
suggested to be potential precursors to melanoma; however,
convincing documentation of a clearly benign proliferative
nodule itself later becoming malignant is difficult to find in
the literature,10 and has not been seen in our practice. How-
ever, in Table 1 we report a case where a benign proliferative
nodule was completely resected at birth, and 5 years later a
melanoma arose at the same site, suggesting progression, or
that some areas may be susceptible to both types of prolifera-
tion.
Neuroid overgrowth areas have poorly defined edges, are
usually round or ovoid/fusiform, are several centimetres to
> 20 cm in diameter, can be less pigmented than the
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Fig 2. Congenital melanocytic naevus
(CMN) – histological features in the nervous
system (a–e) and skin (f–h). (a, b) Images of
leptomeningeal disease showing a cellular
collection of melanocytes with minimal atypia
and no significant proliferation, confirmed on
Ki67 labelling (b) (patient 3, Table 1). (c–e)
In contrast, proliferation of markedly atypical
cells with frequent mitotic figures and a high
Ki67 labelling index (e). The lesion expresses
markers of melanocytes (HMB45). (f–h) Areas
in a proliferative nodule within a cutaneous
CMN demonstrating typical small deep
melanocytes admixed with expansile areas
formed of spindled cells and areas with larger
cells with eosinophilic cytoplasm; there is no
significant atypia and no mitoses are seen.
H&E, haematoxylin and eosin.
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surrounding CMN or pink/red, and are soft or lipoma-like to
the touch (Fig. 1d). As a result of their softness they can
become pendulous. These are not common at birth, usually
developing at any time in childhood and often growing
slowly over years. They have a strong predilection for certain
areas of the body, in particular the flanks within CMN cover-
ing the back and sides, or on the buttocks. Histopathologically
these lesions usually show so-called ‘neuroid differentiation’,
being composed of nodules of bland spindle cells within a
variably myxoid stroma, without significant cytological atypia
or necrosis. A history of transformation to melanoma within
this type of lesion has not been reported.
The genetic basis of congenital melanocytic
naevus
Postzygotic genetics
In single CMN, as with any single lesion, it is difficult to
assign a causative mutation. Genes described as mutated in
single CMN (or possibly single samples taken from patients
with multiple CMN) include NRAS,11,12 BRAF,11,13–18
MC1R,11,19 TP5311 and GNAQ.20 However, in multiple CMN
and CMN syndrome it is possible to assign causality to postzy-
gotic mutations in NRAS in 80% of cases studied, as the same
mutation is found in different cutaneous lesions from the
same patient, and in affected neurological and malignant tis-
sue.5 Causal mutations in multiple CMN usually lead to amino
acid substitutions in codon 61, with p.Q61K being more com-
mon than p.Q61R, and with no distinguishable phenotypic
differences between these two from existing data. However,
numbers of p.Q61R are relatively low and this picture may
change.18,21 NRAS p.Q61H has also been described, but is con-
fined to the rarer naevus spilus phenotypic subtype, a group
that also so far contains a single report of a p.G13R muta-
tion22 and a p.Q61L.23
BRAF p.V600E mutations can also be found in individuals
with large or multiple CMN18 but thus far have not been
found in more than one lesion in the same individual, and
cannot therefore yet be assigned as causal.
Germline genetics
Despite the known postzygotic nature of multiple CMN and
CMN syndrome, a family history of CMN of any size and
number in a first- or second-degree relative has been docu-
mented in one-third of cases in one large cohort.5,24 In this
same cohort a significant increase in compound heterozygous
or homozygous melanocortin-1 receptor (MC1R) variants was
discovered in children with CMN, and this was shown to be
associated with a positive family history.19 Furthermore, cer-
tain MC1R variants were associated with a more severe cuta-
neous phenotype.19 The mechanism for the interaction
between the inherited and postzygotic mutations is not yet
understood; however, this pattern mirrors that of sporadic
adult melanoma. Whether patients with CMN with germline
MC1R variants are at an increased risk of melanoma develop-
ment is not yet known.
The genetics of proliferative nodules
It is known to be difficult to differentiate benign proliferative
nodules from early melanoma arising within CMN using clini-
cal findings and histopathology alone. Immunohistochemistry
of histologically-benign and atypical proliferative nodules in
CMN found that Ki67 and phosphohistone H3 staining have
been relatively useful at distinguishing the two, although there
was no difference in clinical outcome between the two
groups.20 Benign and malignant tumours within cutaneous
CMN have also been demonstrated to harbour differences in
chromosomal copy-number pattern.25 CMN tissue without a
proliferative area shows a ‘normal’ pattern of copy-number
changes (i.e. no large gains or losses, where large is defined
as > 1 MB), benign proliferative nodules typically show copy-
number changes involving whole chromosomes only, and
melanoma typically shows multiple large gains and losses of
parts of chromosomes (Fig. 3). This clear distinction in copy-
number patterns with benign and malignant behaviour from
this first study has not always been replicated in other studies,
with both histopathologically and clinically benign nodules
occasionally exhibiting regional rather than whole chromo-
some copy-number changes, and clinically and histopathologi-
cally malignant nodules the opposite.26,27 As with
immunohistochemical studies, copy-number measurement can
therefore be seen as a very useful adjunct to other assessment,
rather than a definitive test of malignancy.
Melanoma in congenital melanocytic naevus
Melanoma incidence and presentation
Patients with CMN have long been known to be at risk of
melanoma. Here we will review the evolution of the under-
standing of this risk, including our own latest prospective
cohort data, analysed with respect to different aspects of the
congenital phenotype.
Early estimates of melanoma risk were inaccurate due to
small study size, the retrospective (often post mortem) nature
of the analyses,28 and confusion over terminology for CNS
disease. Prospective studies of larger groups and systematic lit-
erature reviews have now established that the incidence of
melanoma is low, of the order of 1–2%.28–31 However, this is
an average figure for all CMN and the incidence actually varies
enormously with the severity of the congenital pheno-
type.28,29 The risk for small single CMN is very low,28,29
whereas where the largest CMN is > 40 cm projected adult
size, and accompanied by multiple smaller CMN, the lifetime
risk has been estimated at 10–15%.28,29 A further complica-
tion is that in a substantial proportion of cases the primary
melanoma develops within the CNS rather than the
skin.24,28,32 A recent review of the literature suggests that pri-
mary CNS melanoma accounts for approximately one-third of
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melanoma occurring in patients with CMN;32 however, the
exact risk is difficult to quantify due to historical difficulties in
differentiating congenital neurological abnormalities from CNS
melanoma, and from the historical assumption that the pre-
sentation of CNS melanoma must have been a secondary from
an unknown primary in the skin.
Long-term prospective studies in our cohort have found
CNS melanoma to be more common in childhood than cuta-
neous melanoma, (Table 1).33 In this cohort of 450 patients
there have been 12 cases of melanoma; however, for two of
these there is uncertainty whether they were referred before
melanoma development, so they were excluded from all inci-
dence calculations. This reduces the cohort to 448, and clinical
phenotyping data for this cohort are given in Appendix S1
(see Supporting Information). In the whole group the inci-
dence of melanoma in childhood (0–16 years) is 22%, with
a mean and median age at death from melanoma of 39 and
25 years, respectively. All 10 cases were in children with
multiple CMN (two or more at birth), and seven of 10 cases
occurred in the group where the largest CMN was > 60 cm
projected adult size or where there were multiple CMN with
no large naevus. This gives an incidence of melanoma in chil-
dren with CMN > 60 cm projected adult size of 8%, and an
incidence of 1% in those who are in any other cutaneous phe-
notypic group (Table 2). Reliable data on the total number of
naevi at first presentation were available in only seven cases,
and in four of seven they had > 50 naevi in total. It is worth
noting that the patients with CMN in our tertiary centre have
phenotypically more severe disease than in the spectrum of
CMN seen in the general population.
However, recent data have shown that the risk of melanoma
appears to be higher in those with congenital abnormalities of
the CNS.33 In line with this, melanoma incidence in the group
of multiple CMN with an abnormal screening magnetic reso-
nance imaging (MRI) of the CNS in the first year of life was
still higher, at 12%, whereas in those with a normal screening
scan it was 1–2% (Table 2). In logistic regression modelling
of any-site melanoma, an abnormal screening MRI of the CNS
(a) (b)
(d)(c)
Fig 3. Congenital melanocytic naevus (CMN) – clinical photographs and representative array comparative genomic hybridization traces from
chromosome 1 from a new nodule within a scalp CMN that was resected (a, b), but recurred as full-blown cutaneous melanoma within weeks (c,
d) (patient 12 in Table 1). The comparative genomic hybridization data from the nodule demonstrate mosaicism for copy-number gains and
losses, which are then easily seen and called by the program (red and green highlighted areas) in the melanoma sample. The only difference
clinically between this nodule and those in Figure 2 was the more rapid rate of growth and failure to stabilize. Written consent was obtained for
publication.
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in the first year of life was the strongest statistical predictor,
better than any clinical phenotyping variable (odds ratio of
all-site melanoma with an abnormal MRI 167, 95% confi-
dence interval 30–923, P = 0001, when the model was cor-
rected for projected adult size). CNS screening MRI is
therefore currently the best predictor of all adverse outcomes
in children, with those with a normal scan being in a low-risk
group for all complications, independent of the rest of their
clinical phenotype.
It is not yet clear why there is such a strong association
between screening CNS MRI results and overall risk of mela-
noma. It could be because CNS melanoma is more common in
our cohort and that this is the real association with abnormal
CNS MRI rather than all-site melanoma. Other possible explana-
tions are that abnormal MRI is an indicator of a higher burden
of mutated cells in the body as a whole, or that the mutation in
those with complex congenital neurological disease happened
at a particular stage of development, or that those with an
abnormal MRI have other genetic risk factors predisposing both
to congenital neurological disease and malignancy.
Cutaneous melanoma arising in CMN usually presents as a
new nodule or lump,32,34 arising mainly in the deeper dermis
or subcutis, and generally with a high Breslow thickness at
presentation.32 These features were found in the cases of cuta-
neous melanoma arising in our prospective cohort (Table 1),
where local lymphadenopathy due to metastasis was also a
presenting feature.
Primary CNS melanoma in individuals with multiple CMN
can present in different ways. These are either as a solid
tumour within the brain parenchyma, or more commonly as
leptomeningeal melanoma, a diffuse and rapidly progressive
proliferation of melanin-producing cells within the lep-
tomeninges. These two can exist separately, but where they
coexist they can be physically unconnected,35 or the lep-
tomeningeal melanoma can invade the underlying parench-
yma.36 Patients can present with focal neurological symptoms
such as seizures, and/or with signs and symptoms of raised
intracranial pressure.33,37,38 This is secondary to diffuse mela-
nocytic leptomeningeal disease, which may not be evident on
MRI at the time of presentation, although hydrocephalus usu-
ally is; in these cases we suggest that a repeat MRI should be
performed after 2 weeks if symptoms persist, and the lep-
tomeningeal disease is usually then detectable. Very rarely-
described is diffuse leptomeningeal disease that stabilizes and
does not progress to death.33,39 Stable focal leptomeningeal
deposits are also described.33,38
The histopathological examination of all of these lep-
tomeningeal lesions can be challenging. Biopsies show cellular
collections of melanocytes, which may show a variety of mor-
phological features but typically have minimal atypia or prolif-
eration, and no invasion of CNS parenchyma (Fig. 2).
Transformation to malignancy is defined histologically by
unequivocal invasion of the CNS parenchyma, and/or cytolog-
ical atypia and cellular proliferation (Fig. 2). However, the
prognosis is often poor despite the lack of classical cytological
hallmarks of malignancy. The whole clinical picture should
therefore be taken together, and a very high index of suspi-
cion maintained.
Table 2 Most recent analysis of incidence of melanoma in children (age 0–16 years) with congenital melanocytic naevus (CMN) by different
phenotypic groupings
Phenotypic subdivisions of the same
cohort
n/N (%) of cutaneous
melanoma in childhood
n/N (%) of primary
CNS melanoma
in childhood
n/N (%) of melanoma
with lymph node (n = 1)
or missing data primary
site (n = 2)
Total n/N (%) of
melanoma in childhood
Single CMN of any size 0/82 (0) 0/82 (0) 0/82 (0) 0/82 (0)
Multiple CMN where the largest
CMN is < 60 cm projected adult
size
2/199 (1) 0/199 (0) 1/199 (< 1) 3/199 (1)
Multiple CMN where the largest
CMN is > 60 cm projected adult
size, or where there is no one
clearly larger CMN
0/88 (0) 6/88 (7) 1/88 (1) 7/88 (8)
Multiple CMN of any size or number
and a normal screening MRI of the
CNS
1/179 (< 1) 1/179 (< 1) 1/179 (0) 3/179 (2)
Multiple CMN of any size or
number, and the finding of any
congenital neurological disease seen
on screening MRI of the CNS
1/51 (2) 5/51 (10) 0/51 (4) 6/51 (12)
Data collected prospectively from our U.K. cohort, 1988–2016, where face-to-face phenotyping occurred and melanoma was not present at
the time of referral (n = 448). Ten children developed melanoma in this prospective cohort, of whom nine had had a screening magnetic
resonance imaging (MRI) of the central nervous system (CNS). Multiple CMN is defined as two or more at birth. Where numbers do not
add up to 448 this is because of individual items of missing data in the older phenotyping data.
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Melanoma has very rarely been described in sites other than
the skin or CNS, specifically the lymph nodes24 and the
retroperitoneum.40 Children with CMN can also rarely develop
tumours other than melanoma, most commonly rhabdomyo-
sarcoma.
The genetics of melanoma in congenital melanocytic
naevus
It has been demonstrated that further mutations are required
to cause malignant transformation in a CMN. Those described
relating to NRAS are loss of the normal allele in NRAS,5 in that
case not secondary to a deletion and therefore probably due
to postmitotic recombination, and amplification of mutant
NRAS.41 Mutations in BRAF have not been described in mela-
noma arising in a patient with CMN; however, given the
availability and efficacy of BRAF inhibitors it is suggested that
both NRAS and BRAF hotspots should be genotyped in cases of
melanoma.
Copy-number measurement is a well-established test to aid
melanoma diagnosis,42,43 and changes in cutaneous melanoma
arising in CMN are described above. Recent data have demon-
strated that the same pattern of changes is also seen in CNS
melanoma in patients with CMN,35 namely large gains and/or
losses of parts of or whole chromosomes. This has confirmed
that new or rapidly progressive CNS disease in patients with
CMN, often previously termed ‘symptomatic neurocutaneous
melanosis’, is, as interpreted by many experts in the field, pri-
mary melanoma of the CNS. This therefore is a clinically use-
ful test as an adjunct to clinical, radiological and
histopathological assessment in all types of suspected mela-
noma arising in patients with CMN.
Melanoma monitoring
Given the rarity of cutaneous melanoma in single CMN of any
size routine monitoring is not recommended. In addition, at
the moment, there is no evidence that clinical monitoring for
cutaneous melanoma in children with multiple CMN or CMN
syndrome makes any difference to outcome, and abandoning
routine monitoring is arguably reasonable for either physicians
or patients. This is partly due to the difficulty in treatment of
melanoma in this condition, which in itself is partly due to
the difficulty in detection of melanoma within very large
CMN. However, regular contact with patients with multiple
CMN is often required in childhood for skincare, neurodevel-
opmental follow-up, coordination of psychological support,
treatment of pruritus or superficial infections where they arise,
resection of small CMN where it can clearly improve cosmetic
appearance, and to some degree reassurance of contact with a
doctor in case it is needed. The basis of skin monitoring with
many and extensive naevi is high-quality photography. Most
children with multiple CMN have lesions that are too large
and too numerous to be visualized systematically by der-
moscopy; however, mole mapping or monitoring by photog-
raphy on a semiautomated basis may be helpful to look for
changes. For smaller CMN, dermoscopic features have been
well delineated.44
The picture with regards to monitoring for CNS melanoma is
changing. In the same way as a patient with benign CMN at
birth can develop a cutaneous melanoma, so there can be con-
genital CNS disease that is benign and stable, or the patient can
develop a CNS melanoma. This distinction has not historically
been made very clear in the literature, with all types of CNS dis-
ease being grouped under the term ‘neurocutaneous melano-
sis’, with some effort to differentiate different types of disease
by using the term ‘symptomatic neurocutaneous melanosis’.
This is an inappropriate term as many children with benign
stable melanotic disease of the CNS have very substantial symp-
toms such as neurodevelopmental delay or seizures, but do not
have a poor prognosis with respect to life expectancy.33,38
Monitoring for CNS melanoma ideally requires a single
screening MRI to characterize the congenital disease in the
CNS if any, and therefore to act as a baseline should the child
present with new neurological symptoms at any stage in life.
For this we recommend a brain and whole-spine MRI with
gadolinium contrast under the age of 1 year (under 6 months
ideally) for anyone with two CMN at birth independently of
size or site.29,33 This can be considered comparable with a
proper examination and documentation of the skin. This rec-
ommendation is made on the basis that in our institution we
do not routinely use general anaesthesia for this procedure
under the age of 1 year. However, even if this is not an
option the scan is pivotal in giving an accurate prognosis, and
radically alters clinical management.
The rationale for scanning at all is to stratify the manage-
ment of patients, as the scan result has been shown to be the
best statistical predictor of clinical outcomes,33 including mel-
anoma (Table 2). The rationale for scanning under the age of
6 months is for best visualization of the characteristic signal
for melanin under MRI, before full myelination takes place. If
normal, the screening scan does not need to be repeated rou-
tinely, and no other CNS monitoring is specifically required,
and as this applies to 80% of cases is highly reassuring for
both clinicians and the families. If the MRI demonstrates the
relatively common finding of intraparenchymal melanosis,
imaging does not require repeating routinely, but we suggest
that annual neurodevelopmental monitoring should be under-
taken until school age as there is an increased incidence of
neurodevelopmental problems and seizures in this group.33
This annual monitoring should allow the early detection of
developmental issues (for example speech delay) and the
implementation of the best care package for the child (for
example speech therapy).
In the small group (<10%) where the MRI demonstrates
any other abnormality, regular clinical and/or radiological
monitoring is advised, as there is a high incidence of neurode-
velopmental abnormalities and seizures and a high rate of
needing neurosurgery, and this group appears to be at highest
risk of melanoma (Table 2).33 Clinical and radiological moni-
toring should be designed on an individual basis, as this is a
very heterogeneous group. Repeat MRI would be
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recommended in all cases of leptomeningeal disease until the
clinical and radiological appearances are definitely stable, as
this presentation is known to evolve into melanoma in many
reported cases.33,38
Independent of the initial screening MRI findings, all fami-
lies of children with multiple CMN should be made aware that
they should present promptly to a clinician if the child devel-
ops signs of raised intracranial pressure at any age, or develops
new cutaneous lumps or other changes.
Historically all decisions regarding melanoma monitoring in
CMN have been based on the severity of the cutaneous pheno-
type, with significant variation in worldwide practice, and
have been established through experience and a small number
of cohort studies. New clinical classifications that include not
only the size and number of lesions but also colour, hetero-
geneity and rugosity3 may be able to refine this still further
going forward. The recent introduction of routine genotyping
for germline MC1R variants and somatic NRAS and BRAF muta-
tions may also help to identify individuals at highest risk of
melanoma development in the future.
Melanoma diagnosis
Where the diagnosis of cutaneous melanoma arising in a CMN
is suspected clinically, an urgent biopsy should be performed
(excision if possible), with histopathological examination by
at least two experts. NRAS and BRAF hotspot genotyping by
sensitive methods, and array comparative genomic hybridiza-
tion (CGH)–single-nucleotide polymorphism (SNP) array or
fluorescence in situ hybridization (FISH) for copy number are
recommended to improve diagnostic accuracy and to guide
management. Driver mutation genotyping is a routine part of
(a)
(b)
Fig 4. Congenital melanocytic naevus
(CMN) – management pathways for suspected
malignancy. (a) Proposed clinical pathways
for investigation of a patient with CMN with
new neurological symptoms or signs [possible
central nervous system (CNS) melanoma]. (b)
Proposed management of a new lump arising
in a CMN. 4/52, 4 weeks; CGH, comparative
genomic hybridization; FISH, fluorescence
in situ hybridization; LDH, lactate
dehydrogenase; MRI, magnetic resonance
imaging; PET, positron emission tomography.
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assessment of melanoma as this leads to treatment stratification
with targeted therapies. This holds true in the context of CMN
genotyping, particularly as the majority of melanomas will be
NRAS mutated, and BRAF inhibitors are currently contraindi-
cated in NRAS-mutated melanoma due to known paradoxical
activation of RAS by these drugs.45 In addition, second-hit
changes in NRAS have been detected in melanoma in CMN,
including loss of the normal allele5 and copy-number amplifi-
cation.41 Where the diagnosis of melanoma arising within the
CNS is suspected, an urgent MRI of the brain and whole spine
with and without contrast enhancement should be performed,
and ideally compared with the screening MRI undertaken in
the first 6 months of life. Evidence of new suspicious CNS
lesions at any age should be investigated as for melanoma by
fresh-tissue biopsy from the CNS. Sampling of cerebrospinal
fluid is not recommended routinely as a biopsy is superior,
but if a biopsy is not possible for some reason then it may be
contributory, and histology of cerebrospinal fluid has been
described.36
Melanoma management
There are no guidelines for the treatment of melanoma arising
in CMN, or in the CNS of patients with CMN. What is offered
here is a distillation of multidisciplinary experience in one ter-
tiary centre with a special interest in the condition, and these
are suggested guidelines only. Suggested management for a
new neurological presentation and for a new lump are
detailed in Figure 4. Routine surgical excision of CMN is not
part of our management as there is no evidence that it alters
melanoma risk, and those with completely excisable CMN and
no CNS disease are at very low risk.
Once a diagnosis of melanoma is confirmed, baseline stag-
ing investigations should be performed. In most cases of CNS
melanoma, distant metastases do not exist at the time of pre-
sentation or appear to play a role before death from spinal
cord compression. However, in cutaneous melanoma, metasta-
sis to local lymph nodes does occur, and local recurrence
within resection sites is rapid even where excision is reported
as histologically complete.
Due to the aggressive nature of melanoma in the context of
CMN, surgical excision plays an important but usually not a
curative role. For cutaneous melanoma this includes excision
biopsy if possible, or biopsy for confirmation of diagnosis,
with subsequent wide local excision and removal of local
nodal metastases. Leptomeningeal melanoma within the spinal
canal is typically diffuse and circumferential precluding thera-
peutic surgical decompression; however, a ventriculoperitoneal
shunting procedure is key in symptom management. As the
disease progresses, dexamethasone can be useful in the short
term for alleviation of raised intracranial pressure. In late
stages palliative radiotherapy has been found to be useful in
our patients both in leptomeningeal melanoma and in cuta-
neous melanoma to decrease the bulk of disease temporarily.
Animal model data of mitogen-activated protein kinase kinase
(MEK) inhibitor use has recently demonstrated an attenuation
of leptomeningeal disease in a murine model of CMN syn-
drome.46 As a result we have used the MEK inhibitor trametinib
as therapy in a small series of four patients with NRAS-mutated
CNS melanoma (three of whom had CMN).47 This demon-
strated measurable and objective relief of symptoms and signs
in all patients, although to varying degrees. Further treatments
will be needed to address the inevitable progression of mela-
noma in these patients.
Suggested work-up for a patient with CMN and a confirmed
diagnosis of melanoma is the following. (i) Bloods: full blood
count, urea and electrolytes, liver function tests, lactate dehy-
drogenase, lipid profile, vitamin D level and bone profile, thy-
roid function, creatine kinase, glycated haemoglobin level,
total protein and glucose. (ii) Imaging: CNS MRI with
gadolinium contrast, whole-body positron emission tomogra-
phy–computed tomography scan, echocardiogram, electrocar-
diogram and plain radiograph of the wrist and tibial growth
plate. (iii) Tissue sample: biopsy of suspected primary (CNS
including leptomeningeal, or skin), for histopathology, NRAS
and BRAF hotspot genotyping, copy-number analysis (array
CGH or SNP array or FISH). (iv) Other: ophthalmology assess-
ment, urinalysis.
Conclusions
Small single CMN are common birthmarks with very low risk
of melanoma, and do not require routine resection for this
reason. Multiple CMN (two or more, of any size or site) can
have extracutaneous associations, then termed ‘CMN syn-
drome’, and these phenotypes are caused by postzygotic
mosaicism for NRAS mutations in 80% of cases. Individuals
with multiple CMN do have an increased risk of melanoma,
particularly in the presence of congenital neurological abnor-
malities on screening MRI in the first 6 months of life. Mela-
noma can arise either in the skin or as a primary in the brain,
the latter being more common in our prospective study of
affected children, or very rarely in other sites. All forms are
usually highly aggressive and fatal. Histopathology by at least
two experts in the field, plus genetic analysis of driver muta-
tions and copy number can help to differentiate melanoma
from benign proliferative nodules in the skin, or from stable
congenital disease in the CNS. Treatment with MEK inhibition
on a compassionate basis has shown substantial although tem-
porary signs of symptomatic improvement of disabling neuro-
logical symptoms in a small series of patients with CNS
melanoma.
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